United Kingdom· GB-APID-40692811000001106
Bylvay 400microgram capsules
A odevixibat product containing odevixibat, registered in United Kingdom by Ipsen Ltd. The same ATC class is registered in 15 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Odevixibat is registered in 15 of 19 countries.
Countries holding a registration under ATC A05AX05 (odevixibat), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 9 of them publish a price we can compare per daily dose
Odevixibat · ATC A05AX05
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Spainprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Odevixibat
- Manufacturer
- Ipsen Ltd
- Country
- United Kingdom (GB)
- ATC code
- A05AX05
- ATC class
- Odevixibat
- Defined daily dose
- 2.4 mg, O
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 1
- gtin09120121720067
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Odevixibat in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NetherlandsBylvay 400 microgram harde capsulesIpsen Pharma
- PolandBylvayIpsen Pharma
- SwedenBylvay 400 mikrogram Kapsel, hårdIpsen Pharma
- SpainBYLVAY 400 MICROGRAMOS CAPSULAS DURASIpsen Pharma
- United StatesBylvayIpsen Biopharmaceuticals, Inc.
- SwitzerlandBylvay 400 μg, HartkapselnIPSEN Pharma Schweiz GmbH
- IrelandKAYFANDA 400 microgram hard capsulesIpsen Pharma
- CanadaBYLVAYMEDISON PHARMA CANADA INC.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Bylvay, Kayfanda
- Liechtenstein · Bylvay, Kayfanda
- Norway · Bylvay, Kayfanda
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/1ea8d839-8e49-4daa-8b14-c79a872bb491 GET /v1/drugs/1ea8d839-8e49-4daa-8b14-c79a872bb491?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "40692811000001106",
"desc": "Bylvay 400microgram capsules (Ipsen Ltd)",
"form": "Oral capsule",
"vpid": "40700611000001101",
"source": "dmd",
"vtm_id": "1179275005",
"strength": "400 microgram",
"substance": "Odevixibat",
"ingredient": "Odevixibat sesquihydrate",
"supplier_code": "3394701000001100"
}See everything about odevixibat.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.